Table 2 Baseline demographic and disease/treatment characteristics of participants randomized to date
| Â | Control | Intervention |
|---|---|---|
n | 64 | 61 |
Male (%) | 39 (60.9) | 34 (55.7) |
Median age (IQR) | 15.9 (13.6 – 17.5) | 16.2 (14.0 – 17.8) |
Race (%) | Â | Â |
 White | 42 (65.6) | 43 (70.5) |
 Black | 9 (14.1) | 6 (9.8) |
 Asian | 4 (6.3) | 3 (4.9) |
 American Indian/Alaska Native | 2 (3.1) | 1 (1.7) |
 Hawaiian/Other Pacific Islander | 2 (3.1) | 0 (0) |
 Other | 5 (7.8) | 8 (13.1) |
Hispanic (%) | 4 (6.3) | 7 (11.5) |
Median years since transplant (IQR) | 3.7 (0.8-7.5) | 4.4 (1.5-8.4) |
Primary disease (%) | Â | Â |
 CAKUT | 30 (46.9) | 21 (34.4) |
 Glomerulonephritis | 3 (4.7) | 6 (9.8) |
 FSGS | 6 (9.4) | 9 (14.8) |
 Other | 23 (35.9) | 21 (34.4) |
 Missing | 2 (3.1) | 4 (6.6) |
Number of immunosuppressive medications (%) | Â | Â |
 1 | 3 (4.7) | 4 (6.6) |
 2 | 27 (42.2) | 21 (34.4) |
 3 | 34 (53.1) | 35 (57.4) |
 4 | 0 (0.0) | 1 (1.6) |
Median total number of all medications (IQR) | 6 (5 - 9) | 7 (5 - 9) |